Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Teun M Post

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|January 15, 2013
Application of a mechanism-based disease systems model for osteoporosis to clinical dataTeun M Post, Stephan Schmidt, Lambertus A Peletier, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 28, 2020
A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIVVera E Bukkems, Teun M Post, Angela P Colbers, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 13, 2023
Building an adaptive dose simulation framework to aid dose and schedule selectionRichard Hooijmaijers, Ridhi Parasrampuria, Eleonora Marostica, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 19, 2023
Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myelomaJon Collins, Martijn van Noort, Chetan Rathi, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 18, 2019
Nonlinear Mixed-Effects Model Development and Simulation Using nlmixr and Related R Open-Source PackagesMatthew Fidler, Justin J Wilkins, Richard Hooijmaijers, et al.
Clinical Pharmacology and Therapeutics|January 29, 2025
Integrated Longitudinal Population Dose-Hemoglobin Response of Daprodustat Following Dose Titration in Patients With Anemia in Chronic Kidney DiseaseKelly M Mahar, Martijn van Noort, Paul van den Berg, et al.
Clinical Pharmacology and Therapeutics|November 1, 2025
Model-Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With AnemiaKelly M Mahar, Shuying Yang, Brendan Johnson, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 2, 2021
Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug developmentPaul van den Berg, Wei Gao, Maurice J Ahsman, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 27, 2019
Performance of the SAEM and FOCEI Algorithms in the Open-Source, Nonlinear Mixed Effect Modeling Tool nlmixrRik Schoemaker, Matthew Fidler, Christian Laveille, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 22, 2025
Tutorial on Conditional Simulations With a Tumor Size-Overall Survival Model to Support Oncology Drug DevelopmentSebastiaan C Goulooze, Morris Muliaditan, Richard C Franzese, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Pharmacokinetics and Pharmacodynamics|January 15, 2013
Application of a mechanism-based disease systems model for osteoporosis to clinical dataTeun M Post, Stephan Schmidt, Lambertus A Peletier, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 28, 2020
A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIVVera E Bukkems, Teun M Post, Angela P Colbers, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 13, 2023
Building an adaptive dose simulation framework to aid dose and schedule selectionRichard Hooijmaijers, Ridhi Parasrampuria, Eleonora Marostica, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 19, 2023
Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myelomaJon Collins, Martijn van Noort, Chetan Rathi, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 18, 2019
Nonlinear Mixed-Effects Model Development and Simulation Using nlmixr and Related R Open-Source PackagesMatthew Fidler, Justin J Wilkins, Richard Hooijmaijers, et al.
Clinical Pharmacology and Therapeutics|January 29, 2025
Integrated Longitudinal Population Dose-Hemoglobin Response of Daprodustat Following Dose Titration in Patients With Anemia in Chronic Kidney DiseaseKelly M Mahar, Martijn van Noort, Paul van den Berg, et al.
Clinical Pharmacology and Therapeutics|November 1, 2025
Model-Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With AnemiaKelly M Mahar, Shuying Yang, Brendan Johnson, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 2, 2021
Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug developmentPaul van den Berg, Wei Gao, Maurice J Ahsman, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 27, 2019
Performance of the SAEM and FOCEI Algorithms in the Open-Source, Nonlinear Mixed Effect Modeling Tool nlmixrRik Schoemaker, Matthew Fidler, Christian Laveille, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 22, 2025
Tutorial on Conditional Simulations With a Tumor Size-Overall Survival Model to Support Oncology Drug DevelopmentSebastiaan C Goulooze, Morris Muliaditan, Richard C Franzese, et al.
Pageof 3